Gossamer Bio, Inc. (GOSS)
10.73
-0.66
(-5.81%)
USD |
NASDAQ |
Sep 11, 16:00
10.58
-0.15
(-1.40%)
After-Hours: 06:45
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 5.245B |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | -96.12% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | 0.6403 |
| Price to Book Value | -- |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | -0.4261 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 99.09% |
Profile
| Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 26, 2015 and is headquartered in San Diego, CA. |
| URL | http://www.gossamerbio.com |
| Investor Relations URL | https://ir.gossamerbio.com/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap Value |
| Next Earnings Release | Nov. 04, 2026 (est.) |
| Last Earnings Release | Aug. 13, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 26, 2015 and is headquartered in San Diego, CA. |
| URL | http://www.gossamerbio.com |
| Investor Relations URL | https://ir.gossamerbio.com/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap Value |
| Next Earnings Release | Nov. 04, 2026 (est.) |
| Last Earnings Release | Aug. 13, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |